Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Liabilities: 2019-2025

Historic Total Liabilities for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $247.9 million.

  • Avidity Biosciences' Total Liabilities rose 80.47% to $247.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.9 million, marking a year-over-year increase of 80.47%. This contributed to the annual value of $138.9 million for FY2024, which is 8.72% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Total Liabilities is $247.9 million, which was up 40.67% from $176.3 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Total Liabilities ranged from a high of $247.9 million in Q3 2025 and a low of $26.0 million during Q2 2021.
  • In the last 3 years, Avidity Biosciences' Total Liabilities had a median value of $127.8 million in 2023 and averaged $124.4 million.
  • Data for Avidity Biosciences' Total Liabilities shows a peak YoY spiked of 146.68% (in 2024) over the last 5 years.
  • Over the past 5 years, Avidity Biosciences' Total Liabilities (Quarterly) stood at $46.1 million in 2021, then skyrocketed by 31.58% to $60.7 million in 2022, then skyrocketed by 110.44% to $127.8 million in 2023, then climbed by 8.72% to $138.9 million in 2024, then skyrocketed by 80.47% to $247.9 million in 2025.
  • Its last three reported values are $247.9 million in Q3 2025, $176.3 million for Q2 2025, and $130.4 million during Q1 2025.